Progress of hepcidin in low-risk myelodysplastic syndromes / 白血病·淋巴瘤

Ineffective hematopoiesis, inflammation and iron overload are involved in the regulation of iron metabolism in myelodysplastic syndromes (MDS). Different types of MDS present different iron states at different stages, hepcidin play a key role in it. Current studies have demonstrated that iron metabolism abnormality is an independent risk factor for the prognosis of low-risk MDS. This article summarizes the research progress of hepcidin in patients with low-risk MDS and further explores the therapeutic prospects of hepcidin in patients with low-risk MDS.